For patienter, som udvikler tegn og symptomer såsom feber, utilpashed, vægttab, svedeture, hoste, dyspnø, og/ eller pulmonale infiltrater eller anden alvorlig systemisk sygdom med eller uden samtidig shock, bør en invasiv fungicid infektion mistænkes, og administration af Humira skal omgående afbrydes og passende antimykotisk behandling iværksættes.
For patients who develop the signs and symptoms such as fever, malaise, weight loss, sweats, cough, dyspnea, and/ or pulmonary infiltrates or other serious systemic illness with or without concomitant shock an invasivie fungal infection should be suspected and administration of Humira should be promptly discontinued and appropriate antifungal therapy should be initiated.